GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (LTS:0K6R) » Definitions » Other Income (Expense)

Neurocrine Biosciences (LTS:0K6R) Other Income (Expense) : $-46 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Neurocrine Biosciences Other Income (Expense)?

Neurocrine Biosciences's other income expense for the Neurocrine Biosciences's pretax income for the three months ended in Dec. 2024 was $18 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-46 Mil.

Neurocrine Biosciences Other Income (Expense) Historical Data

The historical data trend for Neurocrine Biosciences's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Other Income (Expense) Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -188.00 -80.60 -39.20 -115.50 -61.40

Neurocrine Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.00 -69.70 0.40 5.50 17.60

Neurocrine Biosciences Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences  (LTS:0K6R) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Neurocrine Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (LTS:0K6R) » Definitions » Other Income (Expense)
Comparable Companies
VTRS ITCI ALKS ELAN LNTH PBH ALVO PRGO AMRX NDOI ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
NBIX:USA NB3:Germany N1BI34:Brazil
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Website
https://www.neurocrine.com
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines